A new project that will twin the expertise of pregnancy and obstetrics researchers across the world with their counterparts in China has been announced with funding from the Chinese government.
Uncategorized
Ocular Therapeutix™ Outlines Development Strategy for Its Sustained Release Intravitreal Depots to Address Serious Retinal Diseases
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today provided an update on the Company’s development strategy for its sustained release intravitreal depot technology for the treatment of serious retinal diseases. The Company is currently developing proprietary sustained-release hydrogel-based drug delivery depots for intravitreal
Uncategorized
Glaukos Corporation to Release Third Quarter 2016 Financial Results after Market Close on November 10
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, plans to release third quarter 2016 financial results after the market close on Thursday, November 10, 2016. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PST (4:30 p.m. EST) on No
Uncategorized
Ocular Therapeutix™ and Regeneron Enter Into Strategic Collaboration to Develop Sustained Release Formulation of Aflibercept for the Treatment of Wet AMD and Other Serious Retinal Diseases
BEDFORD, Mass–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has entered in…
Uncategorized
CMS plans to overhaul Medicare’s beneficiary identification system: What you need to know
From international law firm Arnold & Porter LLP comes a timely column that provides views on current regulatory and legislative topics that weigh on the minds of today’s physicians and health care executives.CMS is preparing to phase out identification of Medicare beneficiaries by Social Security number (SSN) and will, in their place, roll out a new system of Medicare Beneficiary Identifiers (MBIs). Beginning April 2018, CMS will start issuing new Medicare cards containing MBIs to enrolled beneficiaries and, at the same time, cease issuing cards with SSNs to new enrollees. (Read more...)
Allegro Ophthalmics Announces Positive Topline Results from DEL MAR Phase 2b Trial Evaluating Luminate® in Patients with Diabetic Macular Edema
SAN JUAN CAPISTRANO, Calif.–(BUSINESS WIRE)–Allegro Ophthalmics announced that the DEL MAR Phase 2b clinical trial evaluating Luminate (ALG-1001) in 136 patients with diabetic macular edema met its primary and secondary endpoints.